Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, "Goldilocks" actions at dopamine receptors.
about
Atypicality of atypical antipsychotics.Efficacy and tolerability of pharmacotherapy options for the treatment of irritability in autistic childrenSurvey on schizophrenia treatment in Mexico: perception and antipsychotic prescription patternsRole of Dopamine 2 Receptor in Impaired Drug-Cue Extinction in Adolescent RatsPatterns of antipsychotic prescription to patients with schizophrenia in Korea: results from the health insurance review & assessment service-national patient sample.Efficacy and tolerability of aripiprazole in patients with schizophrenia & schizoaffective disorders.Normalization of risperidone-induced hyperprolactinemia with the addition of aripiprazole.Pathophysiology and treatment of psychosis in Parkinson's disease: a review.An open-label, rater-blinded, augmentation study of aripiprazole in treatment-resistant depressionThird generation antipsychotic drugs: partial agonism or receptor functional selectivity?Aripiprazole-induced oculogyric crisis (acute dystonia)GPCR functional selectivity has therapeutic impact.Two cases of hypersexuality probably associated with aripiprazole.2-Bromoterguride-a potential atypical antipsychotic drug without metabolic effects in rats.Psychotic exacerbation and emotional dampening in the daily life of patients with schizophrenia switched to aripiprazole therapy: a collection of standardized case reports.Treating bipolar disorder in the primary care setting: the role of aripiprazole.Dopamine receptor signaling and current and future antipsychotic drugs.Aripiprazole, a Drug that Displays Partial Agonism and Functional Selectivity.Asenapine monotherapy in the acute treatment of both schizophrenia and bipolar I disorder.Aripiprazole therapy for nicotine dependence.Dysfunction of serotoninergic and dopaminergic neuronal systems in the antidepressant-resistant impairment of social behaviors induced by social defeat stress exposure as juveniles.Low dose of aripiprazole advanced sleep rhythm and reduced nocturnal sleep time in the patients with delayed sleep phase syndrome: an open-labeled clinical observation.
P2860
Q24535908-BD6D1675-4514-4428-84E5-604185460782Q24564288-F746D588-C852-4ED1-8EEC-C9B198BCD106Q24802626-0550451C-7A45-4A19-A963-0200821B60ADQ28273912-8BCD7751-7AED-463C-9B74-25DE42B2C78EQ33627482-D4A0B8CF-DDE1-4183-AF78-21964170BC04Q34174978-98E744AA-20A0-40D1-92A5-6EA6A77D3F40Q34418589-53231974-2412-451B-B226-F15D696611AFQ34610608-4847FC63-7B2A-49B7-A371-61AA9A9B7761Q34642676-2D71D29D-6A31-4A89-B982-6CA9B2E9C9F8Q35012574-E5D8155C-CCDA-4DED-BAE5-7735E1C3953DQ36366047-B010B985-6F50-4D53-BD09-8831B9032E9BQ36880909-E7797B9B-49BA-4835-997C-2E7115BE0590Q36941598-02504CF1-F6D3-4855-BB8B-EC27631EC22EQ37067125-81321B87-40A5-404F-A967-0B74C4891431Q37078959-82FE6E86-D7A2-4BEF-9C07-EFACF86E05BDQ37429721-30D509DB-1DC6-4522-814C-513DF6BA345AQ38058009-8F4E106B-1B80-4A85-A162-385B73B5FCE5Q39244947-709CCAFF-D138-4864-BBE6-68EB223DA996Q41809484-0DE3594E-0588-47AD-91A9-CEF7366F2A53Q41982065-A5263C38-0305-41EE-BF83-55010240F531Q52607023-79E7C247-4F11-493F-BB20-A6001CC020A0Q54936089-3E905A81-C3F3-4132-AB5C-C12125F387D4
P2860
Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, "Goldilocks" actions at dopamine receptors.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Dopamine system stabilizers, a ...... actions at dopamine receptors.
@en
Dopamine system stabilizers, a ...... actions at dopamine receptors.
@nl
type
label
Dopamine system stabilizers, a ...... actions at dopamine receptors.
@en
Dopamine system stabilizers, a ...... actions at dopamine receptors.
@nl
prefLabel
Dopamine system stabilizers, a ...... actions at dopamine receptors.
@en
Dopamine system stabilizers, a ...... actions at dopamine receptors.
@nl
P356
P1476
Dopamine system stabilizers, a ...... actions at dopamine receptors
@en
P2093
P304
P356
10.4088/JCP.V62N1101
P577
2001-11-01T00:00:00Z